Pfizer is steering much of its pandemic revenue into oncology, as Chief Executive Albert ...

NEW YORK, Aug 13 (Reuters) - Drugmakers Pfizer Inc, BioNTech and Moderna Inc are expected to reap billions of dollars from COVID-19 booster shots in a market that could rival the $6 billion in annual ...

STOXX 600 marks fifth week of gains Pfizer COVID-19 pill turbo-charges travel stocks Allegro surges after Mall Group deal German, French stocks scale new peaks Nov 5 (Reuters) - European equities ...

Pfizer will now employ Novavax’s adjuvant, Matrix-M, into its vaccines across two disease areas.

After losing nearly half its value from its 2021 highs, Pfizer stock (NYSE: PFE) now trades at about $25, presenting a potentially attractive value setup. As the company continues to adapt to a ...